By Stockpickr Guest Columnist Glen Bradford

Currently on my radar, I've got at a seasonal company (American Oriental Bioengineering (AOB)) and an exponential company (Cognizant Technology Solutions (CTSH)). Both are underpriced for their long-term risk/reward opportunities. Both have a stronghold in their hemisphere and are looking to begin conquering the other side of the world. The grass always was greener across the street.

AOB is a leading provider of Chinese pharmaceutical products and currently does most of its business in China but is looking to go abroad. In a way, its strategy is like a game of Risk: It's been buying out its competitors and "securing its home country," and now it's looking to take over the entire board.

Cognizant is a leading provider in global custom IT solutions, sourcing mostly out of India and providing for the more established economies. Analysts don't forecast much growth for this company, mostly due to higher operating costs. I think that analysts are being overcautious.

AOB: Although American Oriental Bioengineering is held mostly by institutions, 21% of it is owned by insiders. Currently selling for about $8.50, the market has it underpriced as if it's going to grow at 6% a year. AOB has recently sold $115 million of convertible notes, which raised more than a little suspicion on my part. As it turned out, the company announced that it is spending $110 million to purchase an unnamed Chinese distribution company.

AOB has acquired and teamed up with several companies in the past few years. Investors seem to be concerned with management and share dilution, and I'm a bit cautious myself. The net income growth of AOB has recently been around 40%, but its EPS growth has been around 20%. A company growing this fast should have a conservative P/E ratio of at least 20, but AOB's sits at a modest 12. At a growth rate of 20% year over year, I'm looking for a P/E ratio of 30. Historically, these next two quarters will show improvement. As Jim Cramer would put it: Buy! Buy! Buy!

Cognizant: Cognizant Technology Solutions is priced as if it's going to grow at 13%. The analyst two-year forecast has it growing at 24%, and it's been growing a lot faster than that. It looks like the company's estimates on earnings and revenues are highly conservative; for the past five quarters, Cognizant has twice met and eight times beat revenue and EPS expectations. It's easy to jump over the bar if you set it low enough, but Cognizant sets the bar fairly high, and I'm betting it makes its EPS estimate of 37 cents and continues to beat its peers in the long haul. After all, that's all I'm really concerned about. This is a booyah buy!

Cognizant is looking east while American Oriental Bioengineering is looking west. Both are looking to continue their streak of growth. With a few clicks of the mouse, I plan on capitalizing on their hard work and dedication.

Disclaimer: I own AOB, CTSH.

Posted on Sept. 8, 2008